nordiclifescience.org/he-is-the-euro…

1 in 3 people get cancer. An early-warning system for any kind of cancer could clearly have massive impact. Francesco Gatto and Karl Bergman from Elypta have us convinced - and you?

Elypta utvecklar ett test för att tidigare upptäcka njurcancer. EU investerar för innovation i sjukvården och finansierar Elypta med 24 miljoner svenska kronor. #InvestEU

We are equally thrilled! 🙏👏

We have some good news to share. Our glycosaminoglycan profiling kit is now available as a service for the research community. GAGs play a role in many conditions and we believe standardized, accurate quantification can help others explore this. elypta.com/news-blog/2021…

The cancer detection firm Elypta presents two abstracts using its novel metabolism-based liquid biopsy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021. #Elypta #Chalmersventures #Chalmersftw chalmersventures.com/news/elypta-pr…

Progress!

Big day for us! This funding allows us to validate metabolism as a source for multi-cancer biomarkers along-side genomics, transcriptomics and proteomics. We see great potential to improve early stage sensitivity for MCED without sacrificing specificity. #liquidbiopsy #MCED

Very early cancer detection in healthy people has been studied with liquid biopsy tumor DNA sequencing & methylation. A new report shows the potential for free glycosaminoglycans, both plasma and urine, for 14 cancer types, especially at stage 1 pnas.org/doi/suppl/10.1… PNASNews

A rare tweet from me clearly warranted. This multi-cancer early detection study highlights the exciting potential of GAGomes and Elypta. Great to see it go public!